Zenagamtide

DRUG4 trials

Sponsors

Novo Nordisk A/S

Conditions

Cardiovascular RiskObesityOverweightType 2 Diabetes

Phase 3

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

Not yet recruitingNCT07668401

Novo Nordisk A/SObesity, Overweight

Start: 2027-01-07End: 2029-01-11Target: 400Updated: 2026-08-24

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Not yet recruitingNCT07668414

Novo Nordisk A/SOverweight, Obesity

Start: 2026-09-22End: 2028-10-10Target: 650Updated: 2026-08-25

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Not yet recruitingNCT07720271

Novo Nordisk A/SOverweight, Obesity

Start: 2026-09-01End: 2028-08-22Target: 950Updated: 2026-08-25

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

RecruitingNCT07797335

Novo Nordisk A/SType 2 Diabetes, Cardiovascular Risk

Start: 2026-08-24End: 2028-09-20Target: 1778Updated: 2026-09-01